Saturday 17 October 2026
Export CARM’s income statement to Excel — free account
Carisma Therapeutics Inc.
CARM Healthcare Biotechnology
Carisma Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $19.6 million, up 31.6% from fiscal 2023. In the quarter to September 2025, revenue grew 392.0%, EPS grew 445.2% and free cash flow grew 114.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.00
0.02
−100.00%
Follow CARM
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | 1.36 |
P/S ratio |
0.89 | 0.65 | — | 0.20 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(2.08) | (1.29) | — | 5.91 | |
P/B ratio |
0.00 | 0.00 | — | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | — | 0.00 | |
EV/Sales |
(0.02) | 0.26 | — | 0.15 | |
EV/EBITDA |
0.01 | 0.00 | — | 0.70 | |
EV/Operating CF |
0.01 | (0.11) | — | (0.38) | |
EV/FCF |
0.01 | (0.11) | — | (0.39) | |
Quick Ratio |
1.12 | 0.74 | 0.22 | 0.41 | |
Current Ratio |
1.48 | 1.34 | 0.48 | 0.86 | |
Net Debt/EBITDA |
1.04 | 0.89 | 0.35 | (0.06) | |
Debt/Assets |
0.07% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.33 | 0.44 | 0.00 | 2.30 | |
Operating CF/Net income |
0.47 | 1.09 | 0.60 | 0.04 | |
Capex/Depreciation |
0.00 | 0.79 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
426.44% | 245.53% | 0.00% | 0.44% | |
Selling, General and Administrative Expense of Revenue |
162.33% | 104.77% | 0.00% | 2.74% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
23.32% | 13.62% | 0.00% | 0.93% | |
Graham Net Nets |
(1.98) | (2.99) | — | (0.14) | |
Graham Number |
4.70 | 4.91 | — | 0.00 | |
Earnings Yield |
(347.88%) | (393.90%) | — | 73.67% | |
Free Cash Flow Yield |
(344.83%) | (364.05%) | — | (192.58%) | |
Revenue per Share |
0.09 | 0.09 | 0.00 | 1.08 | |
Operating CF per Share |
(0.20) | (0.24) | (0.14) | 0.05 | |
Capex per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.23) | (0.14) | 0.05 | |
Cash per Share |
0.43 | 0.19 | 0.05 | 0.07 | |
Shareholders Equity per Share |
(0.67) | (0.88) | (1.10) | (0.02) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.67) | (0.88) | (1.10) | (0.02) | |
Free Cash Flow |
(8.35) | (9.54) | (5.74) | 1.91 | |
Working Capital |
7.77 | 3.51 | (4.65) | (0.94) | |
Capital Expenditures |
0.00 | 0.52 | 0.16 | 0.00 | |
Net Current Asset Value |
(34.54) | (38.66) | (46.72) | (1.55) | |
EV/EBIT |
0.01 | 0.00 | — | 0.79 | |
Capex to Sales |
0.00 | (0.14) | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | 1.04 | |
| Other line items | |||||
Average Payables |
3.01 | 2.71 | 3.40 | 3.65 | |
Average Assets |
60.01 | 44.87 | 32.18 | 24.31 | |
Average Common Equity |
(0.69) | (12.88) | (22.82) | (6.00) |
Columns are period end dates